CL2012000238A1 - Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b. - Google Patents
Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b.Info
- Publication number
- CL2012000238A1 CL2012000238A1 CL2012000238A CL2012000238A CL2012000238A1 CL 2012000238 A1 CL2012000238 A1 CL 2012000238A1 CL 2012000238 A CL2012000238 A CL 2012000238A CL 2012000238 A CL2012000238 A CL 2012000238A CL 2012000238 A1 CL2012000238 A1 CL 2012000238A1
- Authority
- CL
- Chile
- Prior art keywords
- hemophilia
- conjugate
- encodes
- polypeptide
- factor
- Prior art date
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 2
- 229960004222 factor ix Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 208000031220 Hemophilia Diseases 0.000 title 1
- 208000009292 Hemophilia A Diseases 0.000 title 1
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 2
- 108010076282 Factor IX Proteins 0.000 abstract 1
- 208000009429 hemophilia B Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23055109P | 2009-07-31 | 2009-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2012000238A1 true CL2012000238A1 (es) | 2012-10-05 |
Family
ID=43529743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2012000238A CL2012000238A1 (es) | 2009-07-31 | 2012-01-30 | Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20120164130A1 (forum.php) |
| EP (1) | EP2461821A4 (forum.php) |
| JP (1) | JP2013500726A (forum.php) |
| KR (1) | KR20120060209A (forum.php) |
| CN (1) | CN102573890A (forum.php) |
| AU (1) | AU2010278721A1 (forum.php) |
| BR (1) | BR112012002072A2 (forum.php) |
| CA (1) | CA2769258A1 (forum.php) |
| CL (1) | CL2012000238A1 (forum.php) |
| CR (1) | CR20120052A (forum.php) |
| CU (3) | CU20120018A7 (forum.php) |
| DO (1) | DOP2012000030A (forum.php) |
| EA (1) | EA201290069A1 (forum.php) |
| EC (1) | ECSP12011637A (forum.php) |
| GT (1) | GT201200023A (forum.php) |
| IN (1) | IN2012DN00908A (forum.php) |
| MX (1) | MX2012001346A (forum.php) |
| PE (1) | PE20121643A1 (forum.php) |
| SG (1) | SG178119A1 (forum.php) |
| WO (1) | WO2011014890A1 (forum.php) |
| ZA (1) | ZA201200716B (forum.php) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745680B2 (en) | 2015-08-03 | 2020-08-18 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3323430A1 (en) | 2006-12-15 | 2018-05-23 | Baxalta GmbH | Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life |
| HRP20230259T1 (hr) | 2008-09-15 | 2023-04-28 | Uniqure Biopharma B.V. | Mutant polipeptida faktora ix, njegove primjene i postupak za njegovu proizvodnju |
| NZ623810A (en) | 2009-07-27 | 2015-10-30 | Lipoxen Technologies Ltd | Glycopolysialylation of non-blood coagulation proteins |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| DK2459224T3 (en) | 2009-07-27 | 2016-07-25 | Baxalta GmbH | Blodstørkningsproteinkonjugater |
| EP2459226B1 (en) | 2009-07-27 | 2016-06-29 | Lipoxen Technologies Limited | Glycopolysialylation of proteins other than blood coagulation proteins |
| AR082941A1 (es) * | 2010-07-30 | 2013-01-23 | Baxter Int | Metodo para conjugar un polimero hidrosoluble a una porcion de carbohidrato oxidado de una proteina terapeutica |
| EA032056B1 (ru) | 2010-12-22 | 2019-04-30 | Баксалта Инкорпорейтид | Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты) |
| HRP20180124T1 (hr) * | 2011-12-19 | 2018-02-23 | Dilafor Ab | Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba |
| AU2013348029A1 (en) * | 2012-11-20 | 2015-07-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor IX proteins |
| KR20150126035A (ko) | 2013-03-13 | 2015-11-10 | 일라이 릴리 앤드 캄파니 | 변형된 개 렙틴 폴리펩티드 |
| TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| CA3034566A1 (en) | 2016-07-27 | 2018-02-01 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor ix function |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| TW202027799A (zh) | 2018-10-18 | 2020-08-01 | 美商英特利亞醫療公司 | 用於表現因子ix的組成物及方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002086091A2 (en) * | 2001-04-25 | 2002-10-31 | The Regents Of The University Of California | Method to treat hemophilia by hepatic gene transfer of factor viii/ix with vesicle vector |
| EP1694315A4 (en) * | 2003-12-03 | 2009-10-28 | Novo Nordisk As | FACTOR IX GLYCOPEGYL |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| EP2423305A1 (en) * | 2006-06-19 | 2012-02-29 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
-
2010
- 2010-08-02 PE PE2012000114A patent/PE20121643A1/es not_active Application Discontinuation
- 2010-08-02 MX MX2012001346A patent/MX2012001346A/es not_active Application Discontinuation
- 2010-08-02 KR KR1020127005191A patent/KR20120060209A/ko not_active Withdrawn
- 2010-08-02 CN CN2010800431356A patent/CN102573890A/zh active Pending
- 2010-08-02 US US13/388,288 patent/US20120164130A1/en not_active Abandoned
- 2010-08-02 CA CA2769258A patent/CA2769258A1/en not_active Abandoned
- 2010-08-02 AU AU2010278721A patent/AU2010278721A1/en not_active Abandoned
- 2010-08-02 BR BR112012002072A patent/BR112012002072A2/pt not_active IP Right Cessation
- 2010-08-02 SG SG2012005757A patent/SG178119A1/en unknown
- 2010-08-02 WO PCT/US2010/044177 patent/WO2011014890A1/en active Application Filing
- 2010-08-02 JP JP2012523129A patent/JP2013500726A/ja active Pending
- 2010-08-02 IN IN908DEN2012 patent/IN2012DN00908A/en unknown
- 2010-08-02 EA EA201290069A patent/EA201290069A1/ru unknown
- 2010-08-02 EP EP10805185.5A patent/EP2461821A4/en not_active Withdrawn
-
2012
- 2012-01-27 DO DO2012000030A patent/DOP2012000030A/es unknown
- 2012-01-30 CU CU20120018A patent/CU20120018A7/es unknown
- 2012-01-30 EC EC2012011637A patent/ECSP12011637A/es unknown
- 2012-01-30 CR CR20120052A patent/CR20120052A/es unknown
- 2012-01-30 GT GT201200023A patent/GT201200023A/es unknown
- 2012-01-30 ZA ZA2012/00716A patent/ZA201200716B/en unknown
- 2012-01-30 CL CL2012000238A patent/CL2012000238A1/es unknown
-
2013
- 2013-04-19 CU CU2013000057A patent/CU20130057A7/es unknown
- 2013-04-19 CU CU2013000058A patent/CU20130058A7/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10745680B2 (en) | 2015-08-03 | 2020-08-18 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN00908A (forum.php) | 2015-04-03 |
| KR20120060209A (ko) | 2012-06-11 |
| US20120164130A1 (en) | 2012-06-28 |
| GT201200023A (es) | 2014-01-27 |
| CR20120052A (es) | 2012-06-04 |
| EA201290069A1 (ru) | 2012-07-30 |
| ZA201200716B (en) | 2013-07-31 |
| JP2013500726A (ja) | 2013-01-10 |
| CU20130057A7 (es) | 2013-06-28 |
| DOP2012000030A (es) | 2012-02-29 |
| CN102573890A (zh) | 2012-07-11 |
| EP2461821A4 (en) | 2013-07-03 |
| WO2011014890A1 (en) | 2011-02-03 |
| MX2012001346A (es) | 2012-02-17 |
| BR112012002072A2 (pt) | 2016-11-08 |
| SG178119A1 (en) | 2012-03-29 |
| ECSP12011637A (es) | 2012-02-29 |
| CU20120018A7 (es) | 2012-06-21 |
| CU20130058A7 (es) | 2013-06-28 |
| PE20121643A1 (es) | 2012-11-25 |
| AU2010278721A1 (en) | 2012-02-16 |
| CA2769258A1 (en) | 2011-02-03 |
| EP2461821A1 (en) | 2012-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2012000238A1 (es) | Polipéptido del factor ix; secuencia de adn que lo codifica; célula huésped eucariota; procedimiento de producción; conjugado; composición que lo comprende; y su uso para el tratamiento de la hemofilia b. | |
| CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
| EA201500172A1 (ru) | Модифицированные полипептиды фактора х и их применение | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
| CL2011002942A1 (es) | Compuestos derivados de 2,4-diamino-pirimidina, agonistas de receptor tipo toll-7 (tlr7); composicion farmaceutica; y su uso para el tratamiento del cancer. | |
| CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
| BR112013010834A2 (pt) | polipeptídeos fator ix modificados e usos dos mesmos | |
| CL2012002250A1 (es) | Compuestos heterociclicos fusionados derivados de pirimidinonas, inhibidores potentes de cdc7; composicion farmaceutica; y su uso en la prevencion o el tratamiento del cancer. | |
| EA201390254A1 (ru) | Модифицированные полипептиды релаксина и их применение | |
| CL2008001632A1 (es) | Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma. | |
| MX379228B (es) | Compuestos y usos de estos para la modulación de la hemoglobina. | |
| MX356641B (es) | Compuestos agonistas dobles de gip-glp-1 y procedimientos. | |
| EA201170242A1 (ru) | Модифицированные бычьи полипептиды g-csf и их применение | |
| NI201000015A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| CL2011001427A1 (es) | Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras. | |
| EA201290541A1 (ru) | Модифицированные бычьи соматотропиновые полипептиды и их применение | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| MX393281B (es) | Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino. | |
| CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
| ES2663096T3 (es) | Métodos para el tratamiento del síndrome nefrótico y de afecciones relacionadas | |
| BR112013013960A8 (pt) | Composi%c3%87%c3%95es de vacinas de mal%c3%81ria, polipept%c3%8ddeos, fragmentos do mesmo, mol%c3%89culas de %c3%81cido nucleico, e usos destes | |
| CL2012000355A1 (es) | Compuestos derivados de 4-amino-butenamida; composicion farmaceutica; y uso en el tratamiento de la epoc. | |
| CY1122901T1 (el) | Προϊοντα συζευξης πρωτεϊνης-πολυμερους |